Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for obesity in young overweight or obese adults
ACTRN12618001958279Phase 2Not yet recruiting
- Sponsor
- Dr Moe Thuzar
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing Spironolactone with Placebo (2 arms). Primary endpoints: Change in total fat mass and Change in insulin sensitivity. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
spironolactone
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12618001958279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001958279.